Data Composite

Drug Recalls

Recent drug recall reports from the FDA (US) and Health Canada, newest first. Each entry links to the full record -- product description, reason for recall, and severity classification -- refreshed daily.

Nitrous Oxide whipped cream chargers

Canada Type I Ongoing · initiated 2026-05-11

Unauthorized product. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any heal…

UCB Biosciences Inc.

US Class II Ongoing · initiated 2026-05-08

Lack of Assurance of Sterility

GHK-Cu & BPC-157 powder

Canada Type I Ongoing · initiated 2026-05-07

Product quality. Verify if your product is affected. Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health c…

Ascend Laboratories, LLC

US Class II Ongoing · initiated 2026-05-05

Failed Dissolution Specifications: Olmesartan Medoxomil content below specifications

Sagent Pharmaceuticals

US Class III Ongoing · initiated 2026-05-04

Failed Impurities/Degradation Specifications

Amerisource Health Services LLC

US Class III Ongoing · initiated 2026-05-01

Cross contamination with other products: API contaminated with trace amounts of Acemetacin API.

Amerisource Health Services LLC

US Class III Ongoing · initiated 2026-05-01

Cross contamination with other products: API contaminated with trace amounts of Acemetacin API.

Safecor Health, LLC

US Class II Ongoing · initiated 2026-05-01

Presence of a Foreign Substance; black particles observed in liquid

Safecor Health, LLC

US Class II Ongoing · initiated 2026-04-30

Labeling: Label Mix-Up: Atomoxetine HCl 25mg Capsule incorrectly labeled as Atomoxetine HCl 10mg Capsule.

Ajanta Pharma Ltd.

US Class II Ongoing · initiated 2026-04-29

CGMP Deviations: Presence of N-nitroso-Duloxetine impurity above FDA recommended limit of 0.83 ppm, identified at the 12-month and 18-month long-term stability …

Ajanta Pharma Ltd.

US Class II Ongoing · initiated 2026-04-29

CGMP Deviations: Presence of N-nitroso-Duloxetine impurity above FDA recommended limit of 0.83 ppm, identified at the 12-month and 18-month long-term stability …

Ajanta Pharma Ltd.

US Class II Ongoing · initiated 2026-04-29

CGMP Deviations: Presence of N-nitroso-Duloxetine impurity above FDA recommended limit of 0.83 ppm, identified at the 12-month and 18-month long-term stability …

Zydus Pharmaceuticals (USA) Inc

US Class II Ongoing · initiated 2026-04-29

CGMP Deviations; presence of N-Nitroso-Desmethyl-Erythromycin above the recommended acceptable intake limit

Zydus Pharmaceuticals (USA) Inc

US Class II Ongoing · initiated 2026-04-29

CGMP Deviations; presence of N-Nitroso-Desmethyl-Erythromycin above the recommended acceptable intake limit

PMS-BUSULFAN 6mg/mL

Canada Type III Ongoing · initiated 2026-04-29

Product quality. Verify if your product is affected. Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health c…

B BRAUN MEDICAL INC

US Class I Ongoing · initiated 2026-04-28

Presence of Particulate Matter.

Oasis Medical, Inc.

US Class II Ongoing · initiated 2026-04-27

Lack of Assurance of Sterility: The recall is being initiated out of an abundance of caution following FDA observations noted during a recent inspection of Exce…

Ascend Laboratories, LLC

US Class II Ongoing · initiated 2026-04-27

Failed Dissolution Specifications

Golden State Medical Supply Inc.

US Class III Ongoing · initiated 2026-04-27

Cross contamination with other products: API contaminated with trace amounts of Acemetacin API.

Golden State Medical Supply Inc.

US Class III Ongoing · initiated 2026-04-27

Cross contamination with other products: API contaminated with trace amounts of Acemetacin API.

Teva Pharmaceuticals USA, Inc

US Class II Ongoing · initiated 2026-04-24

Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufa…

Lupin Pharmaceuticals Inc.

US Class II Ongoing · initiated 2026-04-24

Presence of particulate matter: a white thread-like structure in the cartridge

Wisconsin Pharmacal Company

US Class I Ongoing · initiated 2026-04-24

Microbial Contamination of Non-Sterile Products: confirmed presence of Staphylococcus Aureus.

Lannett Company Inc.

US Class III Ongoing · initiated 2026-04-24

Cross contamination with other products: API contaminated with trace amounts of Acemetacin API.

Sterile.H2O

Canada Type II Ongoing · initiated 2026-04-24

Contamination. Verify if your product is affected. Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health con…